The GLP 1 Conundrum: When Employer Benefits Become Costly The news that Bank of America spends over $250 million annually on GLP 1 weight loss drugs for its employees has sent shockwaves through the business and healthcare communities.
On the surface, it appears to be a tale of corporate largesse, with one of the world's largest banks indulging in an expensive perk to boost employee health.
However, scratch beneath the surface, and this story reveals a complex web of competing interests, skyrocketing costs, and shifting employer employee dynamics.